uridine triacetate

{
  "id": "MLC-T-ONC-009081",
  "term": "uridine triacetate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used in the emergency treatment of adults and children who receive too much fluorouracil or capecitabine or who have heart or central nervous system toxicity or other serious side effects that occur within 4 days of ending treatment with these drugs. Uridine triacetate may help protect healthy cells from some of the side effects caused by certain anticancer drugs. It is a type of chemoprotective agent and a type of pyrimidine analog. Also called PN401, triacetyluridine, and Vistogard.",
    "An orally bioavailable, lipophilic, triacetate prodrug form of the pyrimidine nucleoside, uridine, that can be used for uridine replacement or as an antidote for 5-fluorouracil (5-FU)-induced toxicity. Upon administration, uridine triacetate is deacetylated by esterases to produce uridine and acetate. In turn, uridine is converted to uridine triphosphate (UTP), which competes with fluorouridine triphosphate (FUTP), one of the toxic metabolites of 5-FU, for incorporation into RNA of normal cells. This prevents disruption of RNA synthesis in normal cells and limits toxicity resulting from overdose of 5-FU and 5-FU prodrugs. The FUTP-mediated damage to RNA is the main cause of 5-FU toxicities."
  ],
  "abbreviation": "TAU",
  "synonyms": [
    "PN401",
    "triacetyluridine",
    "Vistogard",
    "tri-O-acetyluridine",
    "vistonuridine"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/uridine-triacetate/"
}